Literature DB >> 12431979

Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells.

Olivia Crociani1, Leonardo Guasti, Manuela Balzi, Andrea Becchetti, Enzo Wanke, Massimo Olivotto, Randy S Wymore, Annarosa Arcangeli.   

Abstract

The role of K(+) channel activity during cell cycle progression has become a research topic of considerable interest. Blocking of K(+) channels inhibits the proliferation of many cell types, although the mechanism of this inhibition is unclear. There is speculation that K(+) channels differentially regulate the electrical potential of the plasma membrane (V(m)) during proliferation. We have demonstrated that in tumor cells the value of V(m) is clamped to rather depolarized values by K(+) channels belonging to the HERG family. We report here that tumor cell lines preferentially express the herg1 gene and a truncated, N-deleted form that corresponds to herg1b. This alternative transcript is also expressed in human primary acute myeloid leukemias. Both HERG1 and HERG1B proteins are expressed on the plasma membrane of tumor cells and can form heterotetramers. The expression of HERG protein isoforms is strongly cell cycle-dependent, accounting for variations in HERG currents along the mitotic cycle. Moreover, the blocking of HERG channels dramatically impairs cell growth of HERG-bearing tumor cells. These results suggest that modulated expression of different K(+) channels is the molecular basis of a novel mechanism regulating neoplastic cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431979     DOI: 10.1074/jbc.M210789200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

1.  Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.

Authors:  Fang Zheng; Huiyu Li; Kaiwei Liang; Yimei Du; Dongmei Guo; Shiang Huang
Journal:  Med Oncol       Date:  2011-12-10       Impact factor: 3.064

Review 2.  The 2P-domain K+ channels: role in apoptosis and tumorigenesis.

Authors:  Amanda J Patel; Michel Lazdunski
Journal:  Pflugers Arch       Date:  2004-05-05       Impact factor: 3.657

3.  Alternative splicing and polyadenylation contribute to the generation of hERG1 C-terminal isoforms.

Authors:  Qiuming Gong; Matthew R Stump; A Russell Dunn; Vivianne Deng; Zhengfeng Zhou
Journal:  J Biol Chem       Date:  2010-08-06       Impact factor: 5.157

Review 4.  HERG1 channelopathies.

Authors:  Michael C Sanguinetti
Journal:  Pflugers Arch       Date:  2009-11-22       Impact factor: 3.657

Review 5.  The enigmatic cytoplasmic regions of KCNH channels.

Authors:  João H Morais-Cabral; Gail A Robertson
Journal:  J Mol Biol       Date:  2014-08-23       Impact factor: 5.469

6.  Expression of potassium channel isoforms mRNA in normal human adrenals and aldosterone-secreting adenomas.

Authors:  R Sarzani; F Pietrucci; M Francioni; F Salvi; C Letizia; E D'Erasmo; P Dessì Fulgheri; A Rappelli
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

7.  hERG1a and hERG1b potassium channel subunits directly interact and preferentially form heteromeric channels.

Authors:  Beth A McNally; Zeus D Pendon; Matthew C Trudeau
Journal:  J Biol Chem       Date:  2017-10-31       Impact factor: 5.157

8.  Expression and immunolocalization of ERG1 potassium channels in the rat kidney.

Authors:  Rolando Carrisoza; Carolina Salvador; Norma A Bobadilla; Joyce Trujillo; Laura I Escobar
Journal:  Histochem Cell Biol       Date:  2009-11-17       Impact factor: 4.304

9.  HERG1 currents in native K562 leukemic cells.

Authors:  María S Cavarra; Silvana M del Mónaco; Yanina A Assef; Cristina Ibarra; Basilio A Kotsias
Journal:  J Membr Biol       Date:  2007-09-01       Impact factor: 1.843

Review 10.  Voltage-gated potassium channels as therapeutic targets.

Authors:  Heike Wulff; Neil A Castle; Luis A Pardo
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.